Table 1 Demographic and baseline characteristics of the study population
Variables | Study Population (N = 398) |
|---|---|
Age (years) | |
Mean ± SD (Range) | 72.2 ± 8.5(47, 93) |
Height (cm) | |
Mean ± SD (Range) | 169.2 ± 5.5(145, 186) |
Weight (kg) | |
Mean ± SD (Range) | 65.9 ± 8.9(44, 102) |
Gleason score | |
N (%) | 341 (85.7) |
≤ 6 | 44 (12.9) |
7 | 116 (34.0) |
≥ 8 | 181 (53.1) |
TNM stage, n (%) | |
T3N0M0 | 97 (24.4) |
T4N0M0 | 10 (2.5) |
T(any)N(any)M+ | 168 (42.2) |
Regional lymph nodes status (N+) | 22 (5.5) |
Othera | 101 (25.4) |
Time since first prostate cancer diagnosis (years)b | |
Mean ± SD (Range) | 0.1 ± 0.7(0, 8) |
Indications to Start Triptorelin Treatment, n (%) | |
First line therapy | |
Locally advanced prostate cancer | 228 (57.3) |
Metastatic prostate cancer | 134 (33.7) |
Othersa | 36(9.1) |
Any anti-androgen therapy, n (%) | |
Yes | 389 (97.7) |
Any surgical history, n (%) | |
Yes | 66 (16.6) |
Prior radiotherapy, n (%) | |
Yes | 16 (4.0) |
Prior endocrine therapy for prostate cancer, n (%) | |
Yes | 14 (3.5) |
Any prior medication, n (%) | |
Yes | 301 (75.6) |
Prior endocrine therapy, n (%) | |
Yes | 299 (75.1) |
Bicalutamide | 259 (65.1) |
Flutamide | 40 (10.1) |
Goserelin | 1 (0.3) |
Any concomitant medication, n (%) | |
Yes | 101 (25.4) |
Concomitant endocrine therapy, n (%) | |
Yes | 95 (23.9) |
Bicalutamide | 79 (19.8) |
Flutamide | 17 (4.3) |